Shell Asset Management Co. Purchases Shares of 108,913 SciClone Pharmaceuticals, Inc. (SCLN)

Shell Asset Management Co. purchased a new stake in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 108,913 shares of the specialty pharmaceutical company’s stock, valued at approximately $750,000. Shell Asset Management Co. owned approximately 0.21% of SciClone Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in SCLN. Karp Capital Management Corp acquired a new position in SciClone Pharmaceuticals in the first quarter valued at about $233,000. Ameriprise Financial Inc. boosted its position in SciClone Pharmaceuticals by 4.9% in the first quarter. Ameriprise Financial Inc. now owns 289,617 shares of the specialty pharmaceutical company’s stock valued at $2,838,000 after buying an additional 13,470 shares in the last quarter. Arizona State Retirement System boosted its position in SciClone Pharmaceuticals by 1.9% in the first quarter. Arizona State Retirement System now owns 26,800 shares of the specialty pharmaceutical company’s stock valued at $263,000 after buying an additional 500 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 310 shares in the last quarter. Finally, OppenheimerFunds Inc. boosted its position in SciClone Pharmaceuticals by 29.9% in the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 3,065 shares in the last quarter. Hedge funds and other institutional investors own 72.80% of the company’s stock.

In other SciClone Pharmaceuticals news, VP Lan Xie sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the transaction, the vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $110,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Hong Zhao sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $330,000.00. Following the completion of the transaction, the chief executive officer now directly owns 30,000 shares in the company, valued at $330,000. The disclosure for this sale can be found here. 5.16% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/11/02/shell-asset-management-co-purchases-shares-of-108913-sciclone-pharmaceuticals-inc-scln.html.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%. The firm had revenue of $44.52 million for the quarter.

SciClone Pharmaceuticals Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

What are top analysts saying about SciClone Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SciClone Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit